Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 2/20 | 0.67 |
| ▸ | ARG2 | P78540 | 4/20 | 0.59 |
| ▸ | ARG1 | P05089 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | GRM8 | O00222 | 1/20 | 0.52 |
| ▸ | GRM6 | O15303 | 1/20 | 0.52 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.52 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.52 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.52 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.52 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.52 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.52 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.52 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684333 | 1.00 | GSR (0.67) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL197363 | 1.00 | GSR (0.67) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL31370204 | 0.98 | GSR (0.64) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL31370110 | 0.98 | GSR (0.64) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL21837616 | 0.98 | GSR (0.64) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL7716428 | 0.98 | GSR (0.64) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL5967486 | 0.98 | GSR (0.64) | GSRARG2ARG1CYP1A2GRM8 | |
| Hydrochloric Acid SCHEMBL21837618 | 0.98 | GSR (0.64) | GSRARG2ARG1CYP1A2GRM8 | |
| SCHEMBL5967324 | 0.98 | GSR (0.64) | GSRARG2ARG1CYP1A2GRM8 | |
| Serine SCHEMBL20262108 | 0.93 | GSR (0.59) | GSRARG2ARG1CYP1A2GRM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 902 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2026-02-17 | — | — | US | claimed |
| WO-2025149851-A2 | METHODS FOR TREATING INFLAMMATORY DISEASES | YUYU PHARMA, INC. (KR) | 2025-07-17 | — | — | WO | claimed |
| CN-119837846-A | Application of magnolol or honokiol derivative in preparation of medicine for neurodegenerative diseases and pharmaceutical composition | 北京红惠新医药科技有限公司 | 2025-04-18 | — | — | CN | claimed |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Universität Zürich (CH) | 2024-08-29 | — | — | US | claimed |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | claimed |
| EP-4295866-A2 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | Virometix AG (CH) | 2023-12-27 | — | — | EP | claimed |
| CN-117106189-A | Metal organic framework artificial hydrolase and preparation method and application thereof | 华南理工大学 | 2023-11-24 | — | — | CN | claimed |
| EP-3638284-B1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIROMETIX AG (CH) | 2023-08-30 | — | — | EP | claimed |
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIROMETIX AG (CH) | 2023-06-20 | — | — | US | claimed |
| WO-2023088062-A1 | ANTI-HYPOXIC/ANOXIC INJURY USE OF MAGNOLOL AND/OR HONOKIOL AROMATIC RING AMINO-SUBSTITUTED DERIVATIVE, AND PHARMACEUTICAL COMPOSITION | 北京红惠新医药科技有限公司 | 2023-05-25 | — | — | WO | claimed |
| EP-1105415-A1 | CHEMICAL SYNTHESIS OF EXOCHELINS | Keystone Biomedical, Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| EP-1105416-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | Keystone Biomedical, Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000071571-A2 | FAP-ACTIVATED ANTI-TUMOR COMPOUNDS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-11-30 | — | — | WO | claimed |
| US-6063919-A | ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) | KEYSTONE BIOMEDICAL, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-2000009547-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| WO-2000009548-A1 | CHEMICAL SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| EP-0784608-B1 | THE MANUFACTURE OF LEVOBUPIVACAINE AND ANALOGUES THEREOF FROM L-LYSINE | DARWIN DISCOVERY LTD (GB) | 1999-12-22 | — | — | EP | claimed |
| US-5952492-A | REACTING A MIXTURE OF DIACID WITH DIMETHYL PIMELATE, HYDROCHLORIC ACID, METHANOL, DIBUTYL ETHER TO FORM INTERMEDIATE, ADDING O-BENZYL HYDROXYLAMINE HYDROCHLORIDE AND TRIETHYLAMINE, ADDITING DI-TERT-BUTYL DICARBONATE | KEYSTONE BIOMEDICAL, INC. (US) | 1999-09-14 | — | — | US | claimed |
| US-5627278-A | MULTISTAGE REACTION FORMED BY AMIDATION, COUPLING AND REDUCTION | BRISTOL-MYERS SQUIBB CO. (US) | 1997-05-06 | — | — | US | claimed |
| EP-0061187-A1 | Bicyclic lactams as antihypertensives | MERCK & CO. INC. (US) | 1982-09-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680085-B2 | Cyclic peptides for protection against respiratory syncytial virus | VIP, LNPEP, CSTB | GSR 1013/4885ARG2 648/4885ARG1 806/4885 |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | GSR 4118/4885ARG2 869/4885ARG1 241/4885 |
| US-20240287143-A1 | CYCLIC PEPTIDES FOR PROTECTION AGAINST RESPIRATORY SYNCYTIAL VIRUS | VIP, QPCT, QPCTL | GSR 1793/4885ARG2 931/4885ARG1 251/4885 |
| US-12552839-B2 | Cyclic peptides for protection against respiratory syncytial virus | CTH, VIP, CXCL10 | GSR 864/4885ARG2 741/4885ARG1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.